Open AccessSubgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)
Author(s) -
Abdulraheem Yacoub,
Uma Borate,
Raajit K. Rampal,
Haris Ali,
Eunice S. Wang,
Aaron T. Gerds,
Gabriela S. Hobbs,
Marina Kremyanskaya,
Elliott F. Winton,
Casey L. O’Connell,
Swati Goel,
Stephen T. Oh,
Gary J. Schiller,
Albert Assad,
Sue Erickson-Viitanen,
Feng Zhou,
Naval Daver
Publication year - 2021
Publication title -
blood
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.515
H-Index - 465
eISSN - 1528-0020
pISSN - 0006-4971
DOI - 10.1182/blood-2021-148668
Subject(s) - ruxolitinib , myelofibrosis , medicine , phases of clinical research , oncology , clinical trial , pharmacology , bone marrow